New and emerging therapeutic agents for the treatment of fibromyalgia: an update

References

• WolfeFSmytheHAYunusMBThe American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria CommitteeArthritis Rheum19903321601722306288
   PubMed Web of Science ®Google Scholar
• CroffordLJPharmaceutical treatment options for fibromyalgiaCurr Rheumatol Rep20046427428015251075
   PubMedGoogle Scholar
• KrypelLLFibromyalgia: A review of its pathophysiology and drug treatmentJournal of Pharmacy Practice2009221616
   Google Scholar
• RooksDSFibromyalgia treatment updateCurr Opin Rheumatol200719211111717278924
   PubMed Web of Science ®Google Scholar
• NeumannLBuskilaDEpidemiology of fibromyalgiaCurr Pain Headache Rep20037536236812946289
   PubMedGoogle Scholar
• Krsnich-ShriwiseSFibromyalgia syndrome: An overviewPhys Ther199777168758996465
   PubMed Web of Science ®Google Scholar
• BennettRMJonesJTurkDCRussellIJMatallanaLAn internet survey of 2,596 people with fibromyalgiaBMC Musculoskelet Disord200782717349056
   PubMed Web of Science ®Google Scholar
• Fibromyalgia Available from: <http://www.niams.nih.gov/Health_Info/Fibromyalgia/default.asp>. 2004. Accessed Sept 28, 2008.
   Google Scholar
• GranJTThe epidemiology of chronic generalized musculoskeletal painBest Pract Res Clin Rheumatol200317454756112849711
   PubMed Web of Science ®Google Scholar
• BuskilaDSarzi-PuttiniPBiology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndromeArthritis Res Ther20068521816887010
   PubMed Web of Science ®Google Scholar
• StaudRBiology and therapy of fibromyalgia: Pain in fibromyalgia syndromeArthritis Res Ther20068320816684376
   PubMed Web of Science ®Google Scholar
• Martinez-LavinMHermosilloAGAutonomic nervous system dysfunction may explain the multisystem features of fibromyalgiaSemin Arthritis Rheum200029419719910707988
   PubMed Web of Science ®Google Scholar
• MaleticVRaisonCLNeurobiology of depression, fibromyalgia and neuropathic painFront Biosci2009145291533819482616
   PubMed Web of Science ®Google Scholar
• PaeCULuytenPMarksDMThe relationship between fibromyalgia and major depressive disorder: A comprehensive reviewCurr Med Res Opin20082482359237118606054
   PubMed Web of Science ®Google Scholar
• ArnoldLMStrategies for managing fibromyalgiaAm J Med200912212 SupplS31S4319962495
   PubMedGoogle Scholar
• GoldenbergDLBurckhardtCCroffordLManagement of fibromyalgia syndromeJAMA2004292192388239515547167
   PubMed Web of Science ®Google Scholar
• HassettALGevirtzRNNonpharmacologic treatment for fibromyalgia: Patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicineRheum Dis Clin North Am200935239340719647150
   PubMed Web of Science ®Google Scholar
• GeisserMEStrader DonnellCPetzkeFGracelyRHClauwDJWilliamsDAComorbid somatic symptoms and functional status in patients with fibromyalgia and chronic fatigue syndrome: Sensory amplification as a common mechanismPsychosomatics200849323524218448779
   PubMed Web of Science ®Google Scholar
• RaoSGClauwDJThe management of fibromyalgiaDrugs Today (Barc)200440653955415349132
   PubMed Web of Science ®Google Scholar
• GajrajNMPregabalin: Its pharmacology and use in pain managementAnesth Analg200710561805181518042886
   PubMed Web of Science ®Google Scholar
• StahlSMFibromyalgia pathways and neurotransmittersHum Psychopharmacol200924Suppl 1S11S1719479906
   PubMed Web of Science ®Google Scholar
• American Pain SocietyGuidelines for the management of fibromyalgia syndrome pain in adults and children Available from: http://www.ampainsoc.org/pub/fibromyalgia.htm. 2005. Accessed Dec 2, 2009.
   Google Scholar
• CarvilleSFArendt-NielsenSBliddalHEULAR evidence-based recommendations for the management of fibromyalgia syndromeAnn Rheum Dis200867453654117644548
   PubMed Web of Science ®Google Scholar
• OwenRTPregabalin: Its efficacy, safety and tolerability profile in fibromyalgia syndromeDrugs Today (Barc)2007431285786318174971
   PubMed Web of Science ®Google Scholar
• SillsGJThe mechanisms of action of gabapentin and pregabalinCurr Opin Pharmacol20066110811316376147
   PubMed Web of Science ®Google Scholar
• CroffordLJRowbothamMCMeasePJPregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trialArthritis Rheum20055241264127315818684
   PubMed Web of Science ®Google Scholar
• StaudREvidence of involvement of central neural mechanisms in generating fibromyalgia painCurr Rheumatol Rep20024429930512126581
   PubMedGoogle Scholar
• SelakIPregabalin (Pfizer)Curr Opin Investig Drugs200126828834
   Google Scholar
• US Prescribing Information for Lyrica (Pfizer) Available from: http://www.lyrica.com/. 2009. Accessed Dec 9, 2009.
   Google Scholar
• EnglemanEAPerryKWMayleDAWongDTSimultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitorNeuropsychopharmacology19951242872957576005
   PubMed Web of Science ®Google Scholar
• KiharaTIkedaMEffects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortexJ Pharmacol Exp Ther199527211771837815331
   PubMed Web of Science ®Google Scholar
• MillanMJBroccoMVeigaSCistarelliLMelonCGobertAWAY 100,635 enhances both the ‘antidepressant’ actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortexEur J Pharmacol19983412–31651679543235
   PubMed Web of Science ®Google Scholar
• MoretCBrileyMEffect of antidepressant drugs on monoamine synthesis in brain in vivoNeuropharmacology19923176796841357575
   PubMed Web of Science ®Google Scholar
• MoretCBrileyMEffects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamusJ Neurochem19976928158229231743
   PubMed Web of Science ®Google Scholar
• MoretCCharveronMFinbergJPCouzinierJPBrileyMBiochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drugNeuropharmacology19852412121112193005901
   PubMed Web of Science ®Google Scholar
• TatsumiMGroshanKBlakelyRDRichelsonEPharmacological profile of antidepressants and related compounds at human monoamine transportersEur J Pharmacol19973402–32492589537821
   PubMed Web of Science ®Google Scholar
• RichelsonEThe clinical relevance of antidepressant interaction with neurotransmitter transporters and receptorsPsychopharmacol Bull200236413315012858153
   PubMedGoogle Scholar
• StahlSMGradyMMMoretBrileyMSNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressantsCNS Spectr200510973274716142213
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CoCymbalta (duloxetine) product information Available from: http://pi.lilly.com/us/cymbalta-pi.pdf. 2009. Accessed Dec 9, 2009.
   Google Scholar
• YyldyzASachsGSAdministration of antidepressants. Single versus split dosing: Meta-analysisJ Affect Disord2001662–319920611578673
   PubMed Web of Science ®Google Scholar
• LantzRJGillespieTARashTJMetabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjectsDrug Metab Dispos20033191142115012920170
   PubMed Web of Science ®Google Scholar
• GredenJFDuloxetine and milnacipranSchatzbergAFNemeroffCBEssentials of Clinical Psychopharmacology2nd edArlington, VAAmerican Psychiatric Publishing, Inc2006171180
   Google Scholar
• BymasterFPBeedleEEFindlayJDuloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptakeBioorg Med Chem Lett200313244477448014643350
   PubMed Web of Science ®Google Scholar
• SharmaAGoldbergMJCerimeleBJPharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitorJ Clin Pharmacol200040216116710664922
   PubMed Web of Science ®Google Scholar
• ShutoSOnoSHaseYSynthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonistJ Med Chem19963924484448528941398
   PubMed Web of Science ®Google Scholar
• GracelyRHJensenKPetzkeFThe effect of milnacipran on pain modulatory systems in fibromyalgia: An fMRI analysis [Abstract]Ann Rheum Dis200867Suppl 2255
   Google Scholar
• MainguyYFunctional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipranHum Psychopharmacol200924Suppl 1S19S2319479905
   PubMed Web of Science ®Google Scholar
• NiddamDMChanRCLeeSHYehTCHsiehJCCentral modulation of pain evoked from myofascial trigger pointClin J Pain200723544044817515743
   PubMed Web of Science ®Google Scholar
• LeknesSTraceyIA common neurobiology for pain and pleasureNat Rev Neurosci20089431432018354400
   PubMed Web of Science ®Google Scholar
• BrosschotJFAarsseHRRestricted emotional processing and somatic attribution in fibromyalgiaInt J Psychiatry Med200131212714611760858
   PubMed Web of Science ®Google Scholar
• MichaelESBurnsJWCatastrophizing and pain sensitivity among chronic pain patients: Moderating effects of sensory and affect focusAnn Behav Med200427318519415184094
   PubMed Web of Science ®Google Scholar
• OwenRTMilnacipran hydrochloride: Its efficacy, safety and tolerability profile in fibromyalgia syndromeDrugs Today (Barc)200844965366019137120
   PubMed Web of Science ®Google Scholar
• PuozzoCLeonardBEPharmacokinetics of milnacipran in comparison with other antidepressantsInt Clin Psychopharmacol199611Suppl 415278923123
   PubMed Web of Science ®Google Scholar
• MajJRogozZDlabogaDDziedzicka-WasylewskaMPharmacological effects of milnacipran, a new antidepressant, given repeatedly on the alpha1-adrenergic and serotonergic 5-HT2A systemsJ Neural Transm2000107111345135911145008
   PubMed Web of Science ®Google Scholar
• US Prescribing Information for Savella (Forest Laboratories, Inc.) Available from: http://www.savella.com/. 2009. Accessed Dec 9, 2009.
   Google Scholar
• ArnoldLMRussellIJDiriEWA 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgiaJ Pain20089979280518524684
   PubMed Web of Science ®Google Scholar
• CroffordLJMeasePJSimpsonSLFibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalinPain2008136341943118400400
   PubMed Web of Science ®Google Scholar
• MeasePJRussellIJArnoldLMA randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgiaJ Rheumatol200835350251418278830
   PubMed Web of Science ®Google Scholar
• WolfeFSmytheHAYunusMBThe American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria CommitteeArthritis Rheum19903321601722306288
   PubMed Web of Science ®Google Scholar
• CalandreEPMorillas-ArquesPRodriguez-LopezCMRico-VillademorosFHidalgoJPregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: An open-label, prospective trialPharmacopsychiatry2007402687117447176
   PubMed Web of Science ®Google Scholar
• DworkinRSharmaUStaceyBChambersRSiffertJLong-term treatment of neuropathic pain and fibromyalgia syndrome with pregabalin in treatment-refractory patientsThe Journal of Pain200563S30S30
   Google Scholar
• ArnoldLMLuYCroffordLJA double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorderArthritis Rheum20045092974298415457467
   PubMed Web of Science ®Google Scholar
• ArnoldLMRosenAPritchettYLA randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorderPain20051191–351516298061
   PubMed Web of Science ®Google Scholar
• RussellIJMeasePJSmithTREfficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trialPain2008136343244418395345
   PubMed Web of Science ®Google Scholar
• ChappellASBradleyLAWiltseCDetkeMJD’SouzaDNSpaethMA six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgiaInt J Gen Med200819110220428412
   PubMedGoogle Scholar
• MeasePJRussellIJKajdaszDKLong-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgiaSemin Arthritis Rheum1172009 [Epub ahead of print]
   Web of Science ®Google Scholar
• ArnoldLMClauwDJWohlreichMMEfficacy of duloxetine in patients with fibromyalgia: Pooled analysis of 4 placebo-controlled clinical trialsPrim Care Companion J Clin Psychiatry200911523724419956462
   PubMedGoogle Scholar
• LoboEDQuinlanTO’BrienLKnadlerMPHeathmanMPopulation pharmacokinetics of orally administered duloxetine in patients: Implications for dosing recommendationClin Pharmacokinet200948318919719385712
   PubMed Web of Science ®Google Scholar
• NagaokaSOhnoMSekiguchiAAn open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptomsInt Clin Psychiatry Clin Practice200484751
   PubMed Web of Science ®Google Scholar
• ToyofukuAMiyakoHA case of temporo-mandibular disorder with fibromyalgia treated with the antidepressant, milnacipranHum Psychopharmacol200419535735815252831
   PubMed Web of Science ®Google Scholar
• PleshOWolfeFLaneNThe relationship between fibromyalgia and temporomandibular disorders: Prevalence and symptom severityJ Rheumatol19962311194819528923373
   PubMed Web of Science ®Google Scholar
• VittonOGendreauMGendreauJKranzlerJRaoSGA double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgiaHum Psychopharmacol200419Suppl 1S27S3515378666
   PubMed Web of Science ®Google Scholar
• ClauwDJMeasePPalmerRHGendreauRMWangYMilnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trialClin Ther200830111988200419108787
   PubMed Web of Science ®Google Scholar
• MeasePJClauwDJGendreauRMThe efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trialJ Rheumatol200936239840919132781
   PubMed Web of Science ®Google Scholar
• BrancoJBrageeGZachrissonOMilnacipran for the treatment of fibromyalgia syndrome: A European multicenter, double-blind, placebo-controlled trial [Abstract]Eur Neuropsychopharmacol200818S4S574S575
   Web of Science ®Google Scholar
• GoldenbergDLClauwDJPalmerRHMeasePChenWGendreauRMDurability of therapeutic response to milnacipran treatment for fibromyalgia. results of a randomized, double-blind, monotherapy 6-month extension studyPain Med2009 [Epub ahead of print]
   Google Scholar
• DetkeMJLuYGoldsteinDJMcNamaraRKDemitrackMADuloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depressionJ Psychiatr Res200236638339012393307
   PubMed Web of Science ®Google Scholar
• ScholzBAHammondsCLBoomershineCSDuloxetine for the management of fibromyalgia syndromeJournal of Pain Research2009299108
   PubMedGoogle Scholar
• GendreauRMThornMDGendreauJFEfficacy of milnacipran in patients with fibromyalgiaJ Rheumatol200532101975198516206355
   PubMed Web of Science ®Google Scholar
• PuozzoCAlbinHVinconGDeprezDRaymondJMAmourettiMPharmacokinetics of milnacipran in liver impairmentEur J Drug Metab Pharmacokinet19982322732799725493
   PubMed Web of Science ®Google Scholar
• PuozzoCLensSRehCLack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressantsClin Pharmacokinet200544997798816122284
   PubMed Web of Science ®Google Scholar
• PuozzoCPozetNDeprezDBaillePUngHLZechPPharmacokinetics of milnacipran in renal impairmentEur J Drug Metab Pharmacokinet19982322802869725494
   PubMed Web of Science ®Google Scholar
• RogozZMargasWDlabogaDGoralskaMDziedzicka-WasylewskaMMajJEffect of repeated treatment with milnacipran on the central dopaminergic systemPol J Pharmacol2000522839210949109
   PubMedGoogle Scholar
• BrileyMMilnacipran, a well-tolerated specific serotonin and norepinephrine reuptake inhibiting antidepressantCNS Drug Reviews19984137148
   Google Scholar
• SewitchMJDobkinPLBernatskySMedication non-adherence in women with fibromyalgiaRheumatology200443564865414983107
   PubMed Web of Science ®Google Scholar
• DobkinPLSitaASewitchMJPredictors of adherence to treatment in women with fibromyalgiaClin J Pain200622328629416514330
   PubMed Web of Science ®Google Scholar
• ClauwDJAlpha-2-delta ligands in fibromyalgia: Is the glass half empty or full?Pain20091451–28919560865
   PubMed Web of Science ®Google Scholar
• GrayPPregabalin in the management of central neuropathic painExpert Opin Pharmacother20078173035304118001262
   PubMed Web of Science ®Google Scholar
• BlumenfeldHTaylorLAThe role of serotonin norepinephrine reuptake inhibitors in the treatment of fibromyalgia: A guide for the physician assistantThe Internet Journal of Academic Physician Assistants200542
   Google Scholar
• LawsonKAre complex therapies required as pharmacological treatments of fibromyalgia?Fut Rheumatol200726599605
   Google Scholar
• FiettaPManganelliPFibromyalgia and psychiatric disordersActa Biomed2007782889517933276
   PubMedGoogle Scholar
• LawsonKTreatment options and patient perspectives in the management of fibromyalgia: Future trendsNeuropsychiatr Dis Treat2008461059107119337451
   PubMedGoogle Scholar
• Vera-LlonchMSadoskyADukesEOsterGImpact of pregabalin on the cost of pharmacotherapy for fibromyalgia from a US perspective [Abstract]The Journal of Pain20089450
   Google Scholar
• KatzRSWolfeFMichaudKFibromyalgia diagnosis: A comparison of clinical, survey, and American College of Rheumatology criteriaArthritis Rheum200654116917616385512
   PubMed Web of Science ®Google Scholar